ORLANDO, Fla. — A second phase 2 trial with the tyrosine kinase 2 (TYK2) inhibitor deucravacitinib has met the primary efficacy endpoints for the treatment of the skin manifestations of cutaneous lupus erythematosus (CLE). Unlike an earlier study, which was restricted to patients with systemic lupus erythematosus (SLE), the most recent trial enrolled patients with […]
The post Phase 2 Trial Supports TYK2 Inhibitor for Cutaneous Lupus first appeared on News Health.
Author : News Health
Publish date : 2025-04-01 10:47:00
Copyright for syndicated content belongs to the linked Source.